title: Phase II study of continuous infusion fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors.
abstract: OBJECTIVE
  Twenty-four patients with rapidly progressive neuroendocrine tumors were treated with a new regimen of continuous infusion fluorouracil for 20 weeks (200 mg/m2/d) together with interferon alfa-2b (5 MU three times per week). Maintenance interferon alfa at the same dose was continued after the initial 20-week period.
  
  
  RESULTS
  Of 15 patients with carcinoid tumors, seven (47%) had an objective response, with a median duration of 20.5 months (range, 8.5 to 41), and five (33%) had stabilization of disease for between 3.5 and 42 months. Improvement in symptoms was reported by 10 patients (67%). Three early deaths occurred, all in patients with advanced disease. Of nine patients with neuroendocrine tumors other than carcinoid, three (33%) had an objective response that lasted 2.5 to 24.5 months, and five had disease stabilization for between 2.5 and 16 months.
  
  
  CONCLUSIONS
  These data, particularly in respect to carcinoid tumors, are encouraging, especially since serious complications from treatment were limited. This regimen is not generally toxic, is well tolerated, and offers useful palliation and symptom control in patients with disease that does not respond to simple pharmacologic manipulations.
authors.affiliation: Cancer Research Campaign, Institute of Cancer Research, Sutton, United Kingdom.
authors.forename: H J
authors.initials: HJ
authors.lastname: Andreyev
authors.forename: P
authors.initials: P
authors.lastname: Scott-Mackie
authors.forename: D
authors.initials: D
authors.lastname: Cunningham
authors.forename: V
authors.initials: V
authors.lastname: Nicolson
authors.forename: A R
authors.initials: AR
authors.lastname: Norman
authors.forename: S S
authors.initials: SS
authors.lastname: Badve
authors.forename: A
authors.initials: A
authors.lastname: Iveson
authors.forename: M C
authors.initials: MC
authors.lastname: Nicolson
mesh_terms: D000328:Adult; D000368:Aged; D002276:Carcinoid Tumor / Q000000981:diagnostic imaging / Q000628:therapy; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging / Q000628:therapy*; D011994:Recombinant Proteins; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D005472:Fluorouracil